Skip to content

Government’s bold action on Hepatitis C should be extended to cancer

It’s a bold step by the Ministry of Health: one which offers a new lease of life to some 500,000 Malaysians who suffer from Hepatitis C.

I would like to congratulate the Health Minister, S Subramaniam, for leveraging on the World Trade Organization’s Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement and national patent laws that allow governments to issue “govern ment use” or “compulsory license” on various grounds.

The “government use” provision or “compulsory license” allows a third party to produce the patented product or process without the consent of the patent owner.

In this instance, the cost of treatment for each Hepatitis C patient using Sofosbuvir will be reduced as much as 99%, from RM357,000 to just RM500.

Malaysia is no stranger to this. In 2003, the government issued a “government use” provision to enable the import of two combination HIV-AIDS drugs from an Indian generic company.

This resulted in the cost to fall and it was estimated that three times more patients were treated.

These actions clearly show that the government needs a political will to make public health accessible and affordable to its people.

Therefore, we urge the Ministry of Health to take one further step and make cancer medicines and treatments affordable as well by invoking
the “compulsory licence” or “government use” provisions.

It is estimated that about 100,000 Malaysians live with cancer at any one time and it is the third biggest killer in the country.

According to the private sector, one in four Malaysians will have cancer by the age of 75.

But patients struggle with high cost of medication, loss of income, loss of lifetime savings, rising cost of living, budget cuts for healthcare, weak management of the healthcare system and other commitments such as mortgage, rent and school fees.

A 2015 survey showed that nearly half of Malaysian cancer patients were financially broke after one year of diagnosis. According to the Sydney-based George Institute for Global Health, 49 percent would use up their savings, 39 percent couldn’t afford to pay for their medication and 19 percent just discontinued treatments altogether.

These were the same concerns faced by Hepatitis C patients until now.

TRIPS provisions such as ‘government use’ or ‘compulsory licenses’ are rights accorded to nation-states that could be invoked when life-saving medicine prices are exorbitant and is detrimental to the welfare of people and patients.

Also, it means that pro-active governments can help to regulate prices of medicine in the interests of the people. Here people are prioritized over big pharma profits.

I would like to thank the various NGOs and others who have lobbied the government over the years to reduce the prices of Sofosbuvir.

And, I look forward to the Ministry of Health’s next announcement, which should ideally be about the huge reduction in costs of medicine and treatment procedures for cancer patients.